Evidence-based hormone replacement therapy guidelines have shifted significantly. Norton Women’s Care providers break down updated MHT safety data, prescribing strategies and when to refer.

Published: August 3, 2026

The data driving hormone replacement therapy guidelines has changed considerably since the Women’s Health Initiative (WHI) study upended prescribing patterns in the early 2000s. Yet many clinicians — particularly those in primary care — are still practicing under assumptions rooted in that now-contextualized research.

In a recent episode of Norton Healthcare’s “MedChat” podcast, a conversation between Kris E. Barnsfather, M.D., and Anna K. Feitelson, M.D., OB/GYNs with Norton Women’s Care, reviewed the current evidence for menopausal hormone therapy (MHT) and offered practical guidance for clinicians at the point of care.

Here’s what primary care providers and OB/GYNs should know.

Defining menopause and perimenopause for treatment purposes

Menopause is defined as starting at 12 months following a patient’s final menstrual period — a relatively straightforward benchmark, though patients with a levonorgestrel-containing IUD may present a diagnostic challenge. Perimenopause, by contrast, is a clinical diagnosis characterized by cycle irregularities, sleep disturbances, hot flashes, mood changes and brain fog in a patient who is still menstruating.

Age and family history matter. A 45-year-old with perimenopausal symptoms is a reasonable candidate for MHT evaluation. A 35-year-old with similar symptoms warrants a broader differential — including premenstrual dysphoric disorder, thyroid dysfunction and other endocrine etiologies — before attributing symptoms to perimenopause.

You don’t need labs to treat perimenopause symptoms

One of the more persistent misalignments between evidence and practice is the reflexive ordering of follicle-stimulating hormone, luteinizing hormone, estradiol or progesterone levels before initiating MHT in perimenopausal patients. Per Dr. Feitelson, those labs are unnecessary. Treatment is based on symptoms, not on lab values. In cycling patients, hormone levels fluctuate day to day, making them unreliable as a prescribing guide. The clinical question is simple: Is this patient symptomatic? If yes, treat accordingly.

Similarly, ultrasound is not a prerequisite for initiating MHT. Patients do not need baseline imaging before starting therapy.

What’s changed in the hormone replacement therapy guidelines

The WHI study enrolled predominantly older, asymptomatic women — average age 63 — who had never been exposed to hormones, and used conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA). The study was designed to assess cardiovascular outcomes, not to model how MHT is actually prescribed for symptomatic menopausal women.

Since then, the field has advanced on several fronts:

• Route of administration matters. Transdermal estrogen bypasses hepatic first-pass metabolism, significantly reducing the risk of venous thromboembolism compared with oral formulations. For most symptomatic patients, transdermal estradiol is now considered a reasonable first-line option.
• Formulation matters. Estradiol behaves differently than CEE at the receptor level. Estradiol engages both alpha and beta estrogen receptors equally and appears to have a more favorable effect on vascular endothelium — with lower associated risks for blood pressure elevation, cardiovascular disease and clotting — compared with CEE, which preferentially binds beta receptors.
• Progesterone type matters. Micronized progesterone has replaced MPA as the preferred progestogen in many clinical contexts. Beyond endometrial protection, micronized progesterone carries mild sedative properties that can benefit patients with MHT-associated sleep disturbances.

The Danish Osteoporosis Prevention Study, which examined estradiol in the context of osteoporosis prevention, found a 50% reduction in all-cause mortality and no increased breast cancer risk in women who initiated hormone therapy at approximately age 50 for standard symptomatic indications. This and similar studies have helped offset the population-level concerns raised by the WHI.

Removal by the Food and Drug Administration (FDA) of the black box warning from MHT reflects this evolving evidence base.

Prescribing framework: A practical approach

First-line option for postmenopausal patients: Transdermal estradiol, available in patches, gels and other delivery formats. Start at a midrange dose, assess symptoms at one to two months and titrate based on patient response. No labs are needed to guide dosing decisions.

Progesterone rules:

• Any patient with an intact uterus requires concurrent progestogen to reduce the risk of endometrial cancer. This includes postablation patients. Ablation does not guarantee complete endometrial destruction, and residual endometrium remains at risk. Additionally, ablation can obscure postmenopausal bleeding, potentially delaying cancer detection — making progestogen protection even more critical in this group.
• Patients who have had a hysterectomy do not require progestogen.

Progesterone dosing considerations: Total estrogen load influences progestogen dosing. Patients with higher body mass index may carry higher baseline endogenous estrogen levels and may benefit from higher micronized progesterone doses.

Combination options: A single patch combining transdermal estrogen and progestogen is available. Oral options include estradiol alone, or a combined oral estradiol/micronized progesterone formulation taken once daily. Dual therapy — patch plus oral micronized progesterone — is another viable strategy.

Symptom reassessment: Patients who were perimenopausal when therapy was initiated may experience worsening symptoms in their early 50s as ovarian function declines further. Increasing the estradiol dose is clinically appropriate in this scenario. Progesterone dose adjustment is not automatically required but should account for body composition and overall estrogen exposure.

Timing of initiation

Current evidence supports initiating MHT within 10 years of menopause onset — the window when most patients are symptomatic and when the benefit-risk profile is most favorable. The previous paradigm of waiting or using the lowest dose for the shortest possible time is no longer supported by the best available evidence.

How long should patients stay on MHT?

There is no definitive maximum duration. The prior five-year limit was derived from WHI-era interpretation and is not supported by current data. Duration should be individualized. Revisit the decision annually. As the evidence evolves, so should the conversation.

Managing discontinuation

Patients stopping MHT — regardless of how long they’ve been on it — will experience estrogen withdrawal. Hot flashes, night sweats and related vasomotor symptoms will recur for an indeterminate period, though typically with less severity than at the time of natural menopause transition. Patients considering stopping should be counseled on what to expect.

When MHT is not appropriate

Absolute contraindications include a personal history of stroke, myocardial infarction (MI), venous thromboembolism or breast cancer. In breast cancer survivors with genitourinary syndrome of menopause, local (vaginal) estrogen is generally appropriate — systemic therapy is not. Emerging data continues to support the safety of vaginal estrogen in this population; oncology collaboration is recommended.

Nonhormonal alternatives

For patients who are not candidates for MHT, options include:

• SSRIs/SNRIs: Paroxetine has FDA approval for vasomotor symptoms; other selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors have supporting evidence.
• Oxybutynin: Has demonstrated effectiveness for vasomotor symptom reduction.
• Gabapentin: May provide benefit for some patients.
• NK3 receptor antagonists (fezolinetant and similar agents): Highly effective for patients with contraindications to estrogen, including those with a history of breast cancer or deep vein thrombosis (DVT). These agents target the neurokinin pathway implicated in hypothalamic thermoregulation — the mechanism through which estrogen withdrawal leads to vasomotor chaos. Cost and hepatotoxicity monitoring (liver function tests at baseline and periodically through early treatment) are key considerations. Long-term data beyond two years are still limited.
• Herbal supplements and acupuncture: Evidence is limited and inconsistent.

Bleeding on MHT: When to act

Irregular spotting in the first six to nine months of initiating MHT is common and often attributable to therapy itself. Beyond six months, or with heavier or persistent bleeding, evaluation is warranted. A pelvic ultrasound is a reasonable initial step. If the endometrial stripe is thin (3 millimeters or less) and no polyp is identified, continuing therapy with close monitoring is often appropriate. If findings are inconclusive or lining is thickened, referral to gynecology for endometrial biopsy or hysteroscopy is indicated.

There is no universal recommendation to discontinue MHT during workup; the decision should be individualized based on clinical probability and patient factors. When in doubt, refer.

Red flags for gynecology referral

• History of stroke, MI, DVT or breast cancer
• Unexplained uterine bleeding beyond the early adjustment period
• Complexity exceeding comfort level for primary care management
• Patients requesting evaluation after long-term MHT cessation

A note for primary care

The gynecology workforce cannot absorb every perimenopausal or menopausal patient who presents with symptoms. Primary care providers are well-positioned to initiate and manage MHT for appropriate candidates — and patients are grateful when someone listens and responds.

The conversation has shifted. The data supports a more confident, individualized approach to MHT. The evidence base today is not the evidence base from 2002.

Continuing medical education

Continuing medical education (CME) credits are available through online learning at NortonHealthcare.com/CME. Click on CME Activities and then Online Activities.

Physicians now can access convenient continuing education through the monthly “MedChat” podcast. “MedChat” fills a unique professional gap and is structured around a conversation addressing key issues for each topic. “MedChat” episodes last 30 minutes, so you can listen on your way to work, while walking the dog, eating your lunch or another convenient time for you.

Subscribe to “MedChat” through Apple, Google or Spotify podcasts or access the “MedChat” podcast here.